This 6 month-long study aims to raise awareness of COVID-19 among Arizona populations disproportionately affected by the virus; Latino, American Indian, and African American communities. If you choose to participate, you will be asked to complete study questionnaires and receive information regarding prevention and treatment of COVID-19 by phone, handouts, text, or social media as well as be provided information regarding prevention and treatment trials that are available for COVID-19.
No study has been performed to prospectively record the presenting complaints, signs, symptoms and comorbidities of children who raised the suspicion of pulmonary embolism (PE). Clinicians must extrapolate what is known about PE in adults to children. Perhaps as a result, the mortality rate of PE is the same in children as it is in adults. On the other hand, tens of thousands of low risk children and adolescents are unnecessarily exposed to increased lifetime cancer risk from ionizing radiation from CT scans done to search for PE they do not have.
We will hold individual interviews of HLBS patients, including a range of racial, ethnic, and socioeconomic perspectives, to discuss current and future Artificial Intelligence/Big Data technologies. Participants will be recruited from University of Arizona affiliated clinical practices or online, offering $25 each for participation in 60-minute discussions, either by phone or video conference
A multi-center, randomized, 36-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT)
Your child is invited to participate because your child has a peanut allergy. The study will last up to 72 weeks where you will take daily study drug, monthly study injections, complete study questionnaires/diaries, food challenge, skin prick tests, breathing tests, and have your blood drawn.
For Dupilumab there are common risks such as: conjunctivitis (pink eye), injection site reaction (swelling, redness, etc.), your child may experience a local or generalized allergic reaction (also known as a hypersensitivity reaction).
A double blinded four year study for children 24 - 47 months with the goal of identifying if injections of Omalizumab (Xolair) for two years, could prevent children from getting Asthma and lessen the severety of their breathing problems as they grow.